Showing 1861-1870 of 5696 results for "".
- New Study Shows Eylea HD with Extended 12- or 16-Week Dosing Demonstrated Noninferior Vision Gains to Standard of Care Eyleahttps://modernod.com/news/lancet-study-eylea-hd-with-extended-12-or-16-week-dosing-demonstrated-noninferior-vision-gains-to-standard-of-care-eylea/2482151/Regeneron announced The Lancet published 1-year results from the pivotal PULSAR and
- Outlook Therapeutics Receives FDA Agreement Under SPA for 90 Day Noninferiority Study, NORSE EIGHThttps://modernod.com/news/outlook-therapeutics-receives-fda-agreement-under-special-protocol-assessment-for-90-day-noninferiority-study-norse-eight/2482077/Outlook Therapeutics announced that it has received written agreement from the FDA under a special protocol assessment (SPA) for the NORSE EIGHT clinical trial protocol evaluating ONS-5010 in wet age-related macular degeneration (AMD) subjects. Additionally, Outlook Therapeutics announc
- Decision on the Adoption of a Sale Plan for Pixium Vision Postponedhttps://modernod.com/news/decision-on-the-adoption-of-a-sale-plan-for-pixium-vision-postponed/2482065/Pixium Vision announced that the decision of the Paris Commercial Court on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings has been postponed to a later date, which will be communicated by the company as soon as it becomes aware of it.</
- Nordic Pharma Completes Acquisition of Visant Medical; Plans to Launch Lacrifill in the US for Dry Eye Diseasehttps://modernod.com/news/nordic-pharma-completes-acquisition-of-visant-medical-plans-to-launch-lacrifill-in-the-us-for-dry-eye-disease/2482021/Amring Pharmaceuticals, a subsidiary of Nordic Group BV (Nordic Pharma), announced the completion of its acquisition of Visant Medical. Financial terms of the deal were not disclosed. The companies say the acquisition unites Nordic Pharma's pharmaceutical e
- Pixium Vision: Date Scheduled for Decision on Adoption of a Sale Planhttps://modernod.com/news/pixium-vison-date-scheduled-for-decision-on-adoption-of-a-sale-plan/2482020/Pixium Vision SA announced that following a hearing on Monday, the Paris Commercial Court will issue its decision on January 16, 2024 on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings. In the event of the opening of judicial l
- NORA Names New Executive and Advisory Board Membershttps://modernod.com/news/nora-names-new-executive-and-advisory-board-members/2481983/The Neuro-Optometric Rehabilitation Association, International (NORA) announced the appointments of its new Executive and Advisory Board members. NORA is an interdisciplinary group of professionals dedicated to providing a complete ocular health evaluation and optimum visual rehabilitation educat
- KeraLink International Provides $2.5 Million in Seed Funding to Enable Development of Bioengineered Corneal Implantshttps://modernod.com/news/keralink-international-provides-25-million-in-seed-funding-to-enable-development-of-bioengineered-corneal-implants/2481970/KeraLink International (KLI) announced $2.5 million in seed funding in Pantheon Vision (PV) to launch the development of a novel advancement to help eradicate corneal blindness in both developed and low- and middle-income countries (LMICs). Pantheon Vision, an early-stage ophthalmic med
- FDA Grants Breakthrough Device Status to Toku’s Patented Cardiovascular Risk AI (CLAiR) Platformhttps://modernod.com/news/fda-grants-breakthrough-device-status-to-tokus-patented-cardiovascular-risk-ai-clair-platform/2481934/Toku announced that the FDA has granted Breakthrough Device designation to its patented CLAiR technology. According to Toku, the CLAiR platform, if cleared by the FDA, will be the first medical device in the US market that can provide affordable, point-of-care and non-invasive
- Roche Stops Clinical Development of Oral Drug Candidate for Diabetic Retinopathyhttps://modernod.com/news/roche-stops-clinical-development-of-oral-drug-candidate-for-diabetic-retinopathy/2481902/Roche has decided to stop development of vicasinabin, an oral drug cadidate being evaluated for non-proliferative diabetic retinopathy, after completing phase 2 trials, according to a FiercePharma
- Myra Vision Announces First-in-Human Use of its Calibreye Glaucoma Drainage Devicehttps://modernod.com/news/myra-vision-announces-first-in-human-use-of-its-calibreye-glaucoma-drainage-device/2481816/Myra Vision announced it has initiated its first-in-human clinical study of the Calibreye System, a glaucoma drainage device with titratable outflow control designed to achieve optimal reduction of IOP for moderate to severe glaucoma patients. The prospective, non-randomized open-label